PYC Therapeutics Expands U.S. Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer

Written by: Editor
Published on: 23 Feb 2021

Seasoned Industry Veteran Brings Over 20 Years of Biotechnology and Pharmaceutical Development Experience, With Deep Expertise in Development of Ophthalmology Drugs. Previously Served in Executive Leadership Roles at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the Ophthalmology subsidiary of Novartis.

PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Glenn Noronha, PhD, as Chief Development Officer. Dr. Noronha will oversee the Company’s translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates which is initially focused on inherited ocular diseases.

Dr. Noronha brings to PYC over 20 years of progressive leadership and research experience across both small and large biotechnology and pharmaceutical companies, with deep expertise in development of ophthalmology drug candidates, through his positions at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the ophthalmology subsidiary of Novartis. He has a proven track record of success with developing, implementing and executing drug development strategy and creating successful business and research and development roadmaps. Dr. Noronha has been involved with 8 Investigational New Drug (IND) applications, and 3 New Drug Applications (NDA) with the U.S. Food and Drug Administration (FDA).

“Glenn brings an unparalleled depth of experience in ophthalmology to our growing U.S. leadership team, along with a demonstrable history of success in building teams, creating and executing drug development strategy from pre-Investigational New Drug (IND) through commercialization, and his appointment strengthens the executive leadership team by adding significant operational expertise,” said Sahm Nasseri, U.S. Chief Executive Officer of PYC Therapeutics. “He will play an essential role in transforming PYC into a clinical-stage company as we progress our pipeline development programs, including VP-001, our lead candidate for retinitis pigmentosa type 11.”

“I am thrilled to join PYC at such a pivotal time as the Company, which is initially targeting inherited ocular diseases, builds its presence in the U.S. and advances its pioneering RNA therapeutics pipeline toward clinical development,” said Dr. Noronha. “I have dedicated my career to developing therapies for ophthalmology patients with conditions where there is unmet or underserved need, and I am excited to collaborate with the dynamic PYC team that also prioritizes this goal.”

Recently at BridgeBio Pharma, Dr. Noronha served as Chief Scientific Officer for the Ophthalmology companies Fortify Therapeutics and Retinagenix Therapeutics developing therapies for patients with ocular conditions with genetic causes, and was Head of Translational Medicine at Navire Pharma. Prior to that, he served as Chief Scientific Officer and headed development at Clearside Biomedical where he focused on developing a unique and first-in-class therapeutic approach to treat patients with uveitis, diabetic eye disease and macular degenerative conditions using both small molecules and gene therapy approaches. Before that, Dr. Noronha served as Vice President of R&D for the Ophthalmology and Gastrointestinal franchises at Sucampo Pharma Americas, Chief Scientific Officer at JW Theriac Pharmaceuticals, Global Project Lead for Retina Development at Alcon, and Director at TargeGen where he played a key role in developing the Ophthamalogy and Oncology Programs. He began his career researching biologics, small molecules and bio-organic chemistry at the University of California, Los Angeles.

Related links